 Outcome measures. The primary outcome measures will be the number and the time to either manic or depressive episodes. The secondary outcome measures will be an average change from baseline in YMRS, HRSD, and CGI scores from baseline until the endpoint of Phase 2. We will also evaluate medication side effects, the need for adjunct lorazepam treatment, the reasons for premature discontinuation, the demographic data, and the medical endpoints HgbA1C, weight changes, lipid profile. We will use SPSS and appropriate statistical methods for statistical analysis. 